A plain language summary of the preliminary results for encorafenib plus binimetinib and pembrolizumab in adults with BRAF V600-mutant melanoma in the STARBOARD study
Sign Up to like & getrecommendations! Published in 2025 at "Future Oncology"
DOI: 10.1080/14796694.2025.2488226
Abstract: Plain Language Summary What is this summary about? This summary describes the initial phase of the STARBOARD study, known as a safety lead-in, which was conducted to compare the safety of two different encorafenib doses… read more here.
Keywords: plus binimetinib; plain language; binimetinib pembrolizumab; language ... See more keywords
Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of the National Cancer Institute"
DOI: 10.1093/jnci/djaf263
Abstract: BACKGROUND Encorafenib is a BRAF inhibitor with a pharmacodynamic profile distinct from that of dabrafenib, including a longer dissociation half-life that may enable more sustained BRAF inhibition. It has been hypothesized that this could translate… read more here.
Keywords: dabrafenib plus; plus binimetinib; melanoma; plus trametinib ... See more keywords
Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.21.02029
Abstract: PURPOSE Dual targeting of the gastrointestinal stromal tumor (GIST) lineage-specific master regulators, ETV1 and KIT, by MEK and KIT inhibitors were synergistic preclinically and may enhance clinical efficacy. This trial was designed to test the… read more here.
Keywords: response; plus binimetinib; imatinib; treatment ... See more keywords
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.21.02659
Abstract: PURPOSE Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the treatment of advanced BRAF V600–mutant melanoma. Here, we… read more here.
Keywords: year; braf v600; encorafenib; v600 mutant ... See more keywords